Table 3.
Response by Treatment Groups
| Nab-P/S n = 65 | Nab-P/G n = 45 | P value | |
|---|---|---|---|
| Target Lesions per RECIST | |||
| Best response, n (%) | |||
| CR | 0 | 0 | |
| PR | 25 (38.5) | 13 (28.9) | |
| SD | 23 (35.4) | 17 (37.8) | |
| PD | 8 (12.3) | 7 (15.6) | |
| NE | 9a (13.8) | 8b (17.8) | |
| ORR | |||
| Overall patients | 38.5% (25/65) | 28.9% (13/45) | 0.299 |
| Evaluated patients | 44.6% (25/56) | 35.1% (13/37) | 0.361 |
| DCR | |||
| Overall patients | 73.8% (48/65) | 66.7% (30/45) | 0.415 |
| Evaluated patients | 85.7% (48/56) | 81.1% (30/37) | 0.552 |
| Primary Lesion | |||
| Best response, n (%) | |||
| CR | 0 | 0 | |
| PR | 20 (30.8) | 10 (22.2) | |
| SD | 28 (43.1) | 19 (42.2) | |
| PD | 3 (4.6) | 2 (4.4) | |
| NE | 14c (21.5) | 14d (31.1) | |
| ORR | |||
| Overall patients | 30.8% (20/65) | 22.2% (10/45) | 0.322 |
| Evaluated patients | 39.2% (20/51) | 32.3% (10/31) | 0.526 |
Notes: aPatients were inevaluable for target lesions per RECIST: loss to follow-up n = 9. bPatients were inevaluable for target lesions per RECIST: loss to follow-up n = 8. cPatients were inevaluable for primary target lesion: loss to follow-up n = 9, without primary lesions after surgery n = 3, lack of specific data of the longest diameter of the primary lesion n = 2. dPatients were inevaluable for primary target lesion: loss to follow-up n = 8, without primary lesions after surgery n = 1, lack of specific data of the longest diameter of the primary lesion n = 5.
Abbreviations: CR, complete response; DCR, disease control rate; Nab-P/S, nab-paclitaxel plus S-1; Nab-P/G, nab-paclitaxel plus gemcitabine; NE, inevaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.